Potassium Chloride + Glucose
Potassium Chloride 0.3% + Glucose 5% Kabi is an aqueous solution of potassium chloride and glucose.
Potassium chloride is a chemical compound (a type of salt) that occurs naturally in the blood. Glucose is
one of the sources of energy for the body. This infusion solution provides 200 kilocalories per liter.
This medicine is used as a source of carbohydrates (sugars) in the prevention and treatment of:
This medicine has a higher concentration than blood (hypertonic solution). The doctor will take this into account when determining the dose for the patient.
Before starting treatment with Potassium Chloride 0.3% + Glucose 5% Kabi, you should inform your doctor or nurse:
The doctor will closely monitor the patient's condition during treatment with this medicine. The doctor will take blood and urine samples to determine the patient's condition. Patients with heart or kidney disease should be monitored closely.
The doctor will consider whether the patient is receiving intravenous nutrition (nutrition administered through a drip into a vein).
In the case of long-term administration of Potassium Chloride 0.3% + Glucose 5% Kabi, the patient may require additional nutrition.
Potassium Chloride 0.3% + Glucose 5% Kabi contains sugar (glucose), which may cause high blood sugar levels (hyperglycemia). In such a situation, the doctor may:
This is especially important in the case of diabetic patients.
Patients should be closely monitored. In cases where proper regulation of water content in the blood is disrupted due to increased secretion of antidiuretic hormone (ADH),
infusion of low-sodium fluids (hypotonic fluids) may lead to low sodium levels in the blood (hyponatremia). This can cause symptoms such as headache, nausea, seizures, drowsiness,
coma, brain swelling, and death, so the occurrence of these symptoms (severe symptomatic encephalopathy with hyponatremia) is considered a life-threatening condition.
Potassium Chloride 0.3% + Glucose 5% Kabi should be administered with particular caution in children.
Newborns, especially premature and low-birth-weight infants, are more susceptible to low or high blood sugar levels(hypo- or hyperglycemia) during intravenous administration of glucose solutions.
You should tell your doctor or nurse about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take. It is especially important to inform your doctor if you are taking:
Potassium Chloride 0.3% + Glucose 5% Kabi should not be administered through the same needle as a blood transfusion.
This may cause red blood cells to break down or clump together.
You should consult your doctor about using Potassium Chloride 0.3% + Glucose 5% Kabi with food and drink.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or nurse before using this medicine.
This medicine may be used in pregnant and breastfeeding women. The doctor will closely monitor the amount of medicine administered to the patient. The doctor will order blood tests to monitor the levels of substances in the blood, as changes in potassium levels can affect the mother's and fetus's heart function.
Particular caution should be exercised when administering this medicine to pregnant women during labor, especially in combination with oxytocin (a hormone used to induce labor and prevent bleeding), due to the risk of hyponatremia.
This medicine does not affect the ability to drive or use machines.
This medicine is administered by a doctor or nurse.
The doctor will determine the dose and method of administration based on the patient's age, weight, clinical and biological condition, hydration status, and reason for treatment. The dose of the medicine also depends on other medicines the patient is taking.
The doctor will monitor the patient's fluid levels, blood acidity, urine flow, and electrolyte levels (especially sodium) in the blood (mainly in patients with high vasopressin levels or patients taking other drugs that enhance vasopressin action), at the start of the infusion and during its administration.
The doctor will determine the infusion rate.
If the patient needs a large volume or rapid infusion, the doctor will monitor the ECG (heart function) recording.
During treatment with Potassium Chloride 0.3% + Glucose 5% Kabi, the doctor will order blood tests to monitor the levels of:
In case of administration of too much medicine (in infusion), the following may occur:
If you have any further doubts about using this medicine, you should consult your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The frequency of side effects is not known.
If you experience any side effects, including any side effects not listed in the leaflet, you should inform your doctor or nurse. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C, 02-222 Warsaw
tel.: +48 22 49 21 301
fax: +48 22 49 21 309
e-mail: ndl@urpl.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
There are no special storage instructions for the medicine.
Do not use this medicine after the expiry date stated on the bottle. The expiry date refers to the last day of the month.
Do not use this medicine if the solution is not clear or if there are visible solid particles. Do not use this medicine if the bottle is damaged.
Potassium Chloride 0.3% + Glucose 5% Kabi is a clear solution, free from visible solid particles.
It is available in 500 ml or 1000 ml LDPE (KabiPac) bottles with a polyisoprene plug and a polyolefin cap.
Pack size: 10 bottles in a cardboard box.
Not all pack sizes may be marketed.
Fresenius Kabi Polska Sp. z o.o.
Al. Jerozolimskie 134
02-305 Warsaw
Labesfal – Laboratórios Almiro, S.A.
Zona Industrial do Lagedo
To obtain more detailed information, you should contact the marketing authorization holder:
Fresenius Kabi Polska Sp. z o.o.
Al. Jerozolimskie 134
02-305 Warsaw
tel.: +48 22 345 67 89
Belgium
Potassium Chloride 0.3% + Glucose 5% Fresenius Kabi
Bulgaria
Калиев хлорид + Глюкоза Каби 3 mg/ml + 50 mg/ml инфузионен разтвор
Estonia
Potassium Chloride/Glucose Fresenius 3 mg/50 mg/ml
France
Chlorure de potassium 0,3% et glucose 5% Kabi, solution pour perfusion
Spain
Cloruro de potasio Kabi 40 mEq/l en Glucosa 5% solución para perfusion EFG
Netherlands
Potassium Chloride 0.3% + Glucose 5% Fresenius Kabi
Ireland
Potassium Chloride 0.3% w/v & Glucose 5% w/v Solution for Infusion
Lithuania
Potassium Chloride/ Glucose Fresenius 3 mg/50 mg/ml infuzinis tirpalas
Latvia
Potassium Chloride/Glucose Fresenius 3 mg/50 mg/ml šķīdums infūzijām
Poland
Kalii chloridum 0,3% + Glucosum 5% Kabi
Portugal
Cloreto de Potássio 0,3% p/v e Glucose 5% p/v Kabi
Slovenia
Kalijev klorid/Glukoza Kabi 3 mg/50 mg v 1 ml raztopina za infundiranje
United Kingdom
Potassium Chloride 0.3% w/v & Glucose 5% w/v Solution for Infusion
Date of last revision of the leaflet:29.06.2018
------------------------------------------------------------------------------------------------------------------------------
Information intended for healthcare professionals only:
The medicine is for single use only. Any unused solution should be discarded.
Only a clear solution, free from visible solid particles and with undamaged packaging, should be used.
Route of administration
Intravenous administration using sterile equipment free from pyrogens.
Intravenous administration of potassium should be performed into a large peripheral vein or central vein, in order to reduce the risk of vein hardening. When administering into a central vein, it should be ensured that the catheter is not located in the atrium or ventricle of the heart, in order to avoid local hyperkalemia.
Solutions containing potassium should be administered slowly.
Infusion rate
To avoid the risk of dangerous hyperkalemia, the infusion rate during potassium administration should not exceed 15 to 20 mmol/hour.
In no case should the recommendations in the "Dosage regimen" section be exceeded.
Dosage
General principles
Due to the risk of hyponatremia, before and during administration of the product, it may be necessary to monitor fluid balance, blood glucose levels, and sodium and other electrolyte levels in the blood, especially in patients with non-osmotic stimulation of vasopressin secretion (syndrome of inappropriate antidiuretic hormone secretion) and in patients receiving agonist drugs of vasopressin.
Monitoring of sodium levels in the blood is particularly important during administration of low-sodium fluids (hypotonic fluids) relative to physiological osmotic pressure. Potassium Chloride 0.3% + Glucose 5% Kabi may become extremely hypotonic after administration due to glucose metabolism in the body.
Dosage regimen
Recommended dosage for the treatment of carbohydrate and fluid deficiencies:
Prevention and treatment of potassium deficiency
Adult patients, elderly patients, and adolescents
The usual dose of potassium used to prevent hypokalemia is up to 50 mmol per day, and similar doses may be suitable for use in mild potassium deficiency. The maximum recommended dose of potassium is 2 to 3 mmol/kg body weight per day.
In the treatment of hypokalemia, the recommended dose is 20 mmol of potassium over a period of 2 to 3 hours (e.g. 7-10 mmol/hour) while monitoring the ECG recording.
The maximum infusion rate should not exceed 15 to 20 mmol/hour.
Patients with impaired kidney function should receive smaller doses.
In no case should the recommendations in the "Dosage regimen" section be exceeded.
Children
In the treatment of hypokalemia, the recommended dosage is 0.3-0.5 mmol/kg body weight/hour. The dose should be determined based on frequent laboratory tests.
The maximum recommended dose of potassium is 2 to 3 mmol/kg body weight per day.
The rate and volume of infusion depend on the patient's age, weight, clinical condition, and metabolism, as well as any concomitant treatment, and should be determined after consultation with a doctor experienced in intravenous fluid therapy in children.
Shelf life of the medicine after first opening
The stability of the medicine after first opening has not been established, so the medicine should be used immediately after first opening.
Shelf life of the ready-to-use medicine (added drugs)
Before use, the chemical and physical stability of each added drug in the pH of Potassium Chloride 0.3% + Glucose 5% Kabi should be established.
Any incompatibilities should be checked before adding any drug to Potassium Chloride 0.3% + Glucose 5% Kabi.
In the absence of compatibility studies, this medicine should not be mixed with other medicines.
The doctor is responsible for assessing the incompatibility of the added drug with Potassium Chloride 0.3% + Glucose 5% Kabi by checking for any change in color and/or precipitation, formation of insoluble compounds or crystals. The instructions for use of the added drug should be consulted.
Before adding the drug, its solubility and/or stability in water at the pH of Potassium Chloride 0.3% + Glucose 5% Kabi (pH: 3.5 - 6.0) should be confirmed.
In accordance with the guidelines, incompatibilities with Potassium Chloride 0.3% + Glucose 5% Kabi have been reported (non-exhaustive list):
Drugs with known incompatibilities should not be added.
From a microbiological point of view, this medicine mixed with added drugs should be used immediately, unless mixing is performed in controlled and validated aseptic conditions. If the medicine is not used immediately, the user is responsible for the storage time and conditions of the prepared solution.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.